Abstract
This chapter moves away from the technical aspects of drug discovery to cover the commercial operations of biopharmaceutical companies. Starting with the global market for prescription medicines, the chapter describes the different types of organizations that conduct pharmaceutical research and development and then covers the customer base, pharmacoeconomics and portfolio management. Lastly, the all-important subjects of intellectual property and generic competition are reviewed in some detail.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
A more detailed historical timeline can be found in http://www.gsk.com/about/history.htm, Accessed 3 Dec 2010.
References
figures from ABPI (2010). http://www.abpi.org.uk/industry-info/knowledge-hub/medicines/Pages/nhs-expenditure.aspx#fig1. Accessed 7 June 2011
Adams CP, Brantner VV (2010) Spending on new drug development. Health Econ 19:130–141
Braun MM et al (2010) Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov 9:519–522
Campbell D, Chui M (2010) Pharmerging shake-up new imperatives in a redefined world. IMS Health, http://www.imshealth.com/pharmergingreport2010. Accessed 3 Dec 2010
Cyranoski D (2010) Shanghai by the numbers. Nature 466:518
DiMasi JA et al (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151–185
Esp@cenet (2010). http://www.espacenet.com/access/index.en.htm. Accessed 3 Dec 2010
IMS Health Press Room Top line industry data (2010). http://www.imshealth.com. Accessed 3 Dec 2010
International Society for Pharmacoeconomics and Outcomes Research (2010). http://www.ispor.org/. Accessed 3 Dec 2010
Johnson T (2010) Healthcare Costs and U.S. Competitiveness. Council on Foreign Relations. http://www.cfr.org/publication/13325/healthcare_costs_and_us_competitiveness.html. Accessed 3 Dec 2010
Knowles SM (2010) Fixing the Legal Framework for Pharmaceutical Research. Science 327:1083–1084
NICE technology appraisal guidance 192 (2010). http://www.nice.org.uk/nicemedia/live/13058/49880/49880.pdf. Accessed 3 Dec 2010
Projan S (2003) Why is big Pharma getting out of antibacterial drug discovery? Curr Opinin Microbiol 6:427–430
UK Department of Health (2007) Departmental Report 2007 of the UK Department of Health. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_074766.pdf. Accessed 3 Dec 2010
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Zanders, E.D. (2011). Commercial Aspects of Drug Development. In: The Science and Business of Drug Discovery. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9902-3_16
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9902-3_16
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-9901-6
Online ISBN: 978-1-4419-9902-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)